Phase III trial of birch-pollen allergy immunotherapy (AllerT) for the treatment of birch pollen allergies

Trial Profile

Phase III trial of birch-pollen allergy immunotherapy (AllerT) for the treatment of birch pollen allergies

Planning
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2015

At a glance

  • Drugs Birch pollen allergy immunotherapy-Anergis (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2015 New trial record
    • 01 Apr 2015 According to an Anergis media release, the dose regimen for this trial will be selected on the basis of the results of phase II trial of AllerT (see profile 700250587).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top